source
- Sling Therapeutics raises $123M Series C to advance oral thyroid eye disease drug into Phase 3Sling Therapeutics announced a $123 million Series C financing round aimed at moving its oral therapy for thyroid eye disease into a late‑stage trial and eventual market launch. The company has be…
- FDA launches expedited IND pilot program, integrating public feedback into qualification criteriaThe FDA announced that its long-awaited expedited investigational new drug (IND) pilot program has started accepting applications as of Tuesday. Agency leaders Karim Mikhail and Michael Davis, new…